Longevity Biotech Investment Surges Ahead of Science

Billions are pouring into longevity biotechnology, with companies raising about $3.74bn in the first quarter of 2026 alone, as investors bet on treating the biology of ageing. Scientists now understand ageing through twelve interconnected cellular processes, and manipulating them in animals has extended lifespan. But experts warn the risks of such interventions remain poorly understood.